Sarepta says ELEVIDYS shows 2-year functional gains in 8-12-year-old Duchenne patients versus external controls at WMS 2026

By Public Technologies
  • Sarepta presented new ELEVIDYS data at the 2026 World Muscle Society annual congress, citing functional benefits in older ambulatory Duchenne patients.
  • Two-year follow-up in boys treated at ages 8-12 showed sustained functional performance versus a matched external control, suggesting slower disease progression.
  • Separate results already shown for children treated at ages 2 to under 3 indicated strong biological drug activity soon after infusion.
  • Safety remained consistent with the established profile, with no new safety signals reported across these analyses.
  • Use in patients under age 4 remains investigational, with longer-term functional outcomes in the youngest group still being tracked.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300830BIZWIRE_USPR_____20260930_BW354567) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.